Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
Sandra Rebouissou, Mohamed Amessou, Gabrielle Couchy, Karine Poussin, Sandrine Imbeaud, Camilla Pilati, Tina Izard, Charles Balabaud, Paulette Bioulac-Sage, Jessica Zucman-Rossi

To cite this version:

HAL Id: inserm-00340859
http://www.hal.inserm.fr/inserm-00340859
Submitted on 25 May 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

Rebouissou Sandra 1, 2, Amessou Mohamed 1, 2, Couchy Gabrielle 1, 2, Poussin Karine 1, 2, Imbeaud Sandrine 3, 4, Pilati Camilla 1, 2, Izard Tina 5, Balabaud Charles 6, 7, Bioulac-Sage Paulette 6, 8, Zucman-Rossi Jessica 1, 2 *

1 Genomique Fonctionnelle des Tumeurs Solides INSERM : U674, Université Denis Diderot - Paris VII, IFR105, Hopital Saint-Louis - IFR 105 PARIS VII 27, Rue Juliette Dodda 75010 PARIS, FR
2 IUH, Institut Universitaire d’Hématologie Université Denis Diderot - Paris VII, Hôpital St Louis, FR
3 Genexpress, Génomique Fonctionnelle et Biologie Systémique pour la Santé CNRS : UMR7091, Université Pierre et Marie Curie - Paris VI 7, rue Guy Moquet, BP8, 94801 Villejuif cedex, FR
4 DNA Microarray Platform (GODMAP) Centre de Génomique Moléculaire, UPR 2167 CNRS, Gif-sur-Yvette, F-91198 France; Université?? Paris-Sud 11, Orsay, F-91405 France
5 Department of Cancer Biology The Scripps Research Institute, Jupiter, Florida, US
6 Service de Hépatologie INSERM : U674, Université Victor Segalen - Bordeaux II, IFR66, 146 rue l'hop saignat, 33076 Bordeaux Cedex, FR
7 Service de Hépato-gastroenterologie CHU Bordeaux, Hôpital Saint-André, Bordeaux, FR
8 service d'anatomie pathologique CHU Bordeaux, Groupe hospitalier Pellegrin, Bordeaux, FR

* Correspondence should be addressed to: Jessica Zucman-Rossi <zucman@cephb.fr>

Abstract

Inflammatory hepatocellular adenomas (IHCA) are benign liver tumours defined by the presence of inflammatory infiltrates and by the elevated expression of inflammatory proteins in tumour hepatocytes 1, 2. Here we show a striking activation of the IL6 signalling pathway in this tumour type, and sequencing candidate genes pinpointed this response to somatic gain-of-function mutations in the IL6ST gene that encodes the signalling co-receptor gp130. Indeed, 60% of IHCA harbour small in-frame deletions that target the binding site of gp130 for IL6, and expression of four different gp130 mutants, in hepatocellular cells, activates STAT3 in absence of ligand. Further, analysis of hepatocellular carcinomas revealed that rare gp130 alterations are always accompanied by β-catenin-activating mutations, suggesting a cooperative effect of these signalling pathways in the malignant conversion of hepatocytes. The recurrent gain-of-function gp130 mutations in these human hepatocellular adenomas fully explains activation of the acute inflammatory phase observed in tumourous hepatocytes, and suggests that similar alterations may occur in other inflammatory epithelial tumours having STAT3 activation.

MESH Keywords Adenoma, Liver Cell ; genetics ; pathology ; Cell Line , Tumor ; Cytokine Receptor gp130 ; genetics ; metabolism ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Inflammation ; genetics ; pathology ; Interferons ; metabolism ; Interleukin-6 ; metabolism ; STAT3 Transcription Factor ; metabolism ; Sequence Deletion ; genetics ; Signal Transduction

Author Keywords hepatocellular adenoma ; hepatocellular carcinoma ; gp130 ; inflammation ; oncogene ; mutation

Several recent studies have shown STAT3 activation in epithelial tumours, underscoring the importance of IL6 signalling and the inflammatory response in tumourigenesis, which provides an opportunity for therapeutic intervention. However, the mechanisms that provoke sustained STAT3 activation in tumours are largely unresolved. To define the interaction between the inflammatory response and carcinogenesis in liver tumours, we assessed inflammatory hepatocellular adenomas (IHCA), benign tumours predominately found in women and frequently associated with obesity and alcohol use 1, 2. Tumour hepatocytes of these adenomas express elevated levels of serum amyloid A (SAA) and C-reactive (CRP) proteins, two members of the acute-phase inflammatory response, whereas SAA and CRP are not expressed in inflammatory cells, Kupffer cells, or other sinusoidal cells in IHCA (Fig. 1a, Supplementary Table S1, and Ref. 1). Inflammatory infiltrates were largely localised to arterial vessels, but were also found within the sinusoidal lumens of IHCA. Here, CD45+ CD3+ T lymphocytes (CD4:CD8, 2:1) were intermingled with less numerous CD20+CD79A+ B cells, some plasma cells and a few polymorphonuclear cells; no CD30+ lymphocytes, nor CD56+ or CD57+ NK cells were observed. In addition, CD68+ histiocytes were present in infiltrates, as well as prominent Kupffer cells in sinusoidal lumens (Supplementary Fig. S1). Overall, inflammatory infiltrates observed in IHCA were highly polymorphous.

To resolve the underlying pathogenesis of these inflammatory lesions, a genome-wide transcriptome analysis of four IHCA was compared to four normal liver tissue samples. Among the 285 genes significantly overexpressed in IHCA (Supplementary Table S1), gene ontology analysis identified a strong enrichment for genes associated with inflammation and the immune response, accounting for 40% of the overall terms significantly enriched (Supplementary Table S2). High levels of significance were found for "antigen processing and presentation of peptide antigen" (P=2.10^-11) and "regulation of the JAK/STAT cascade" (P=10^-7) (Supplementary Table S2).
confirmed this inflammatory signature in an additional 14 IHCA with a clear activation of the acute-phase inflammatory response affecting both type-1 and type-2 acute-phase genes (Fig. 1b and 1c, Supplementary Table S3). Consistent with the known roles of IL6 and JAK-STAT signalling in the acute-phase response4,5, STAT3 mRNA and protein were significantly elevated in IHCA (Fig. 1b and 1c). IHCA also overexpressed several effectors of type-1 and type-2 interferon signalling pathways (e.g., JAK2, STAT1 and STAT2) and their downstream targets (Fig. 1b, 1c). Collectively, these data suggest that IL6 and interferon signalling are the main inflammatory pathways activated in IHCA (Fig. 1d).

Since IL6 was not overexpressed in IHCA and because the inflammatory response was restricted to tumour hepatocytes (Fig. 1a), we reasoned that somatic genetic mutation(s) might account for activation of IL6 receptor signalling in IHCA. We selected IL6ST as a candidate gene since it encoded the cell surface signalling receptor gp130 shared by at least six different cytokines including IL6, IL11, LIF, OSM, CTNF and CT-1. We sequenced the entire gp130 coding region in 43 IHCA and 33 non-inflammatory hepatocellular adenomas. Remarkably, 26 mutations in gp130 were identified specifically in 60% (26/43) of IHCA, and these included 16 unique, small in-frame deletions and one 33 bp in-frame duplication in exon 6 (Fig. 2a and Table 1). Notably, all IL6ST mutations were found in IHCA and all were of somatic origin, as they were not observed in adjacent normal liver tissues. In all cases, IL6ST mutations were monoallelic, and IHCA with these mutations expressed both the wild type and mutated alleles at comparable levels, as judged by sequencing RT-PCR products of IL6ST mRNA (Supplementary Fig. S2).

Binding of IL-6 to its cognate receptor gp80 (encoded by IL6R) induces formation of a high affinity ternary hexameric complex consisting of two molecules each of IL6, IL6R and gp130. Gp130 engagement then activates JAK/Tyk tyrosine kinases and the STAT family of transcription factors9–11. The consequences of the IL6ST in-frame deletions observed in IHCA included the removal of 1 to 26 amino acids neighbouring the IL6/IL6R binding site (also known as CHR E-F loop) located in D2 domain of gp130 (Fig. 2b). We modelled the different deletions and the duplication in the known crystal structure of the wild type IL6/IL6R/gp130 ternary complex (PDB 1PM7). All of these mutations are predicted to disrupt key residues involved in the gp130-IL6 interface. Specifically, the most frequent alterations target residues 186–191, which direct the gp130-IL6 interaction, whereas the remaining deletions and duplication affect the other two loops that contribute to gp130-IL6 interactions (Fig. 2b). Therefore, the gp130-IL6 interface is targeted in IHCA.

To investigate possible functional consequences of these gp130 mutations, we tested the effects of enforced expression of two frequent deletions (S187-Y190del and Y186-Y190del) and two infrequent mutants (V184-Y186del, S187A and K173-D177del) in Hep3B cells, a hepatocellular carcinoma line that activates the acute inflammatory phase following IL6 treatment12. In the absence of IL6 ligand and serum, overexpression of wild type gp130 alone was not sufficient to activate STAT3 and the downstream acute-phase inflammatory genes (Fig. 3 and Refs. 7,13). In contrast, all gp130 IHCA mutants activated an acute phase inflammatory response and induced typical targets of this response, including CRP, SAA2, SPINK1 and FBG (Fig. 3a, 3c). Further, as observed in IHCA, all of these gp130 mutants induced the expression of SOCS3, which normally serves to harness cytokine signalling (Fig. 3a). Mutant gp130 S187-Y190del was constitutively tyrosine phosphorylated and the activity of STAT3 was clearly increased in gp130 S187-Y190del-expressing Hep3B cells (Fig. 3b). Similarly, immunohistochemical analyses of IHCA demonstrated marked increases in nuclear STAT3 phosphorylated at Tyr-705 (Supplementary Fig. S4e–f). Finally, IL6 augmented the induction of CRP in gp130 S187_Y190del-expressing cells, but mutant receptors were not hypersensitive to low doses of IL6 (Fig. 3d). Therefore, gp130 mutants are constitutively active, and they activate STAT3 and inflammatory response genes in the absence of IL6.

A critical step in the activation of intracellular signalling after IL6 binding on gp130 is the formation a hexameric structure that juxtaposes the membrane proximal domains of two gp130 molecules at the cell surface7,14,15. Using co-immunoprecipitation, we showed that the gp130 S187_Y190del IHCA mutant was able to homodimerize or heterodimerize with wild-type gp130 independently of IL6, whereas wild-type gp130 cannot homodimerize (Fig. 3f). Homodimerization of gp130 in absence of ligand has also been previously described for two other gp130 mutants, Y190FV to AAA and Y190A16. Moreover, overexpression of wild-type gp130 impairs the activity of the mutant gp130 S187_Y190del in a dose-dependent manner (Fig 3c); therefore, mutant gp130 activity appears to be driven by its homodimerization that can be competed by the wild-type protein. Interestingly, using a reverse genetic approach in mice, Ernst and collaborators have recently shown that IL11 promotes chronic gastric inflammation and associated tumourigenesis mediated by gp130 and STAT3 activation17. In IHCA, we also found significant increases (6-fold) in the levels of IL11 mRNA (P<0.01) that may serve to amplify gp130/IL6 signalling, despite a modest decrease in the expression of its specific receptor (IL11RA) (Supplementary Fig. S5a). However, in mutant gp130-expressing Hep3B cells IL11 was not induced (Supplementary Fig. S5b), suggesting that elevation of IL11 in IHCA in vivo may occur through secondary effects.

Relationships between activation of IL6 signalling and hepatic tumourigenesis have also been suggested from studies in mice, where transgenics that overexpress both IL6 and IL6R in hepatocytes develop large liver adenomas18. Further, in knock-in mice expressing gp130Y757 mutant, gastric inflammation and subsequent carcinoma development result from STAT3 activation19–21. The IL6 pathway is also known to activate SHP-2/RAS/ERK signalling22. While in humans STAT3 activation is a clear hallmark of gp130-mutated IHCA,
phosphorylated ERK1/2 was only detected in 50% of these tumours (Supplementary Fig. S6a), and phospho-ERK1/2 was not observed in Hep3B overexpressing mutant gp130 (Supplementary Fig. S6b). Thus, in contrast to STAT3 activation, activation of the SHP-2/RAS/ERK pathway does not appear to contribute to all IHCA.

Surprisingly, type 1 and type 2 interferon targets are overexpressed in gp130-mutated IHCA. Their aberrant activation here might be due to gp130-mediated STAT1/STAT2 activation and inefficient negative feedback by SOCS3, which is thought to prevent activation of type 2 interferon genes under physiological conditions.23 Interestingly, the targets in gp130-mutated IHCA include HIF1A that encodes hypoxia-inducible factor-1α which may contribute to VEGF overexpression and the "telangiectatic" phenotype of IHCA (Fig. 1b, 1c). Further, the inflammatory infiltrate that is a hallmark of IHCA may reflect the robust induction (~110-fold) of CCL20 observed in all IHCA (Fig. 1b). Specifically, CCL20 is a chemokine that interacts with CCR6 and that directs chemotraction of a wide spectrum of immune cells including dendritic cells and B and T lymphocytes, and such a scenario could direct or augment the inflammatory response seen in IHCA.

To investigate the possible interaction and cooperation of gp130 activation with other pathways altered in hepatocellular adenoma, we searched in the same series of 76 adenomas for CTNNB1 (encoding β-catenin) and HNF1A mutations (encoding Hepatocyte Nuclear Factor 1α), two genetic alterations frequently associated with hepatocellular adenoma (HCA).2,26,27 HNF1α inactivation (22 cases) and gp130 activation (26 cases) were mutually exclusive in HCA (P<10^{-4}, Fisher exact test, Supplementary Table S4). By contrast, β-catenin activating mutations were found in 12 adenomas, and half of these had associated gp130 mutations. For two IHCA associated with a malignant transformation to carcinoma, both activating gp130 and β-catenin mutations were found (cases 469 and 786, Supplementary Table S4). In one of these cases, we were able to genotype the hepatocellular carcinoma (HCC) and this harboured the same mutations in CTNNB1 and IL6ST as the corresponding IHCA. In contrast, no cases of malignant transformation were observed in gp130-mutated IHCA without a β-catenin mutation (P=0.05, two-tailed Fisher exact test). When we sequenced IL6ST exon 6 in 111 HCC lacking a known history of IHCA28, only two cases were mutated. Interestingly, these tumours were compatible with a malignant transformation of a non-diagnosed IHCA since both mutated HCC had inflammatory infiltrates; they harboured β-catenin-activating mutations and developed in non-cirrhotic liver (Supplementary Table S4). Collectively, these findings suggest cooperation between the IL6 and β-catenin pathways in the malignant transformation of IHCA.

IL6ST mutations were identified in 60% of IHCA. The remaining IHCA were, however, similar in their expression profiles as IL6ST-mutated IHCA (Supplementary Fig. S3) and, accordingly, activated nuclear phospho-STAT3 was also found in all non-mutated IHCA tested (Supplementary Fig. S4f). Sequencing of the functional domains of three gp130 co-receptors (IL6R, LIFR, and OSMR), the functional domains of three transducing proteins (JAK2, JAK1, and TYK2), and of the coding sequence of SOCS3, failed to identify mutations in gp130-non-mutated IHCA. Moreover, these tumours lacked mutations in the exons or intron/exon boundaries of IL6ST, and IL6ST mRNA levels were comparable to those expressed in normal hepatocytes (Supplementary Fig. S4a). Finally, no gain of chromosome 5q copy number at the IL6ST locus was observed using CGH-SNP experiments in gp130 mutated and non-mutated IHCA (data not shown). However, by western blotting and immunohistochemistry, we found that most IHCA cases overexpressed gp130 protein (Supplementary Fig. S4b-d), suggesting that the translation or turnover of gp130 is affected in both gp130-non-mutated and mutated tumours. Therefore, gp130 overexpression and STAT3 activation are related to gp130 activating mutation in 60% of the IHCA, whereas in the non-mutated cases, the mechanism of STAT3 activation remains to be defined. Here, for example, activation may reflect mutations in a regulatory protein(s) that controls gp130 stabilisation, or be due to alterations in factors that control its translation.

The present findings reveal that STAT3 activation and the inflammatory phenotype in benign liver tumours can occur through gain-of-function somatic mutations in gp130. To our knowledge, this is the first identification of somatic mutation of gp130 in tumours and they define gp130 as an oncogene with involvement in benign human tumours. Our findings also underscore the important role of inflammatory response in hepatocellular tumourigenesis and are in accord with a recent study demonstrating that IL6 promotes liver tumour onset in mice.29 Importantly, our studies also suggest that cooperating mutations of the WNT/β-catenin and IL6/STAT pathways in human liver tumours contribute to the occurrence of inflammatory hepatocellular carcinomas that develop in the absence of cirrhosis. More broadly, these findings indicate that this novel mechanism for activation of the IL6 signalling pathway should be interrogated in other human tumours, particularly those having an inflammatory phenotype and STAT3 activation, a hallmark of many epithelial tumours.

Methods summary

All tumours and corresponding non-tumour liver tissues were frozen after surgical resection. These tumours were clinically and genetically characterized; they were previously included in genetic and phenotypic studies (Supplementary Table S4 and refs. 1, 2 and 28). The study was approved by the local Ethics Committee (Paris Saint-Louis), and informed consent was obtained in accordance with French legislation. Transcriptional profiling were performed using Affymetrix oligonucleotide GeneChips HG-U133A and the microarray data have been deposited in Gene Expression Omnibus (GEO) under accession number GSE11819. Quantitative RT-PCR was performed as described30 using pre-designed primers and probe sets from Applied Biosystems (provided in Supplementary Table S5). In all cases the somatic origin of the mutation found in tumour was verified by sequencing the corresponding adjacent, normal liver sample. In HEP3B
cell experiments, all quantitative RT-PCR, luciferase assay and western blotting were performed two days after transfection and after 6 hours of serum starvation.

**Methods**

A series of 76 HCA was analysed. All samples were collected in Bordeaux hospital. They were extensively characterised and included in previous studies. All the 111 HCC were included and described previously. For each tumour, a corresponding frozen non-tumour liver sample was available for analyses.

**Transcriptome analyses**

Transcriptional profiling of four IHCA and four normal liver tissues were performed using Affymetrix oligonucleotide GeneChips HG-U133A (GEO accession number GSE11819). For each case, 5 μg of total RNA were labeled and hybridization was performed using 20 μg of cRNA per hybridization (GeneChip Fluidics Station 400), according to the manufacturer’s instructions (Affymetrix, Santa Clara, CA). Array images were digitized by using Microarray Suite 5.0 (MAS5) software, embedded in the Affymetrix GeneChip Operating Software (Affymetrix, Santa Clara, USA). Gene intensity derivation was carried out from the raw numerical data (CEL files) by using the R package affy31, available as part of the Bioconductor project32, and the DNA-Chip analyzer (dChip) program33. Probe sets corresponding to control genes or having a “_x_” annotation were masked yielding a total of 19,787 probe sets available for further analyses. Background subtraction, normalization and expression summaries for every probe set were calculated with the log-scale robust multi-array analysis (RMA) algorithm using a background adjusted PM intensities model34, and with the model-based expression indexes (MBEI) calculation following a PM/MM difference model33. The log-transformed normalized data was considered for further analysis; and a gene annotation was adjoined using the Unigene cluster identifier as a common primary key (Unigene Build184-June05).

Differential analyses were performed using multiple testing procedures to evaluate statistical significance for differentially expressed genes. The biological groups were compared as independent conditions. A pooled curve-fit error method was used for random error estimation; a range of 3.0 median absolute deviations (MADs) to 4.0 MAD established outlier-detection thresholds automatically. Data were subjected to iterative normalization by centering to the median across biological groups. Statistical analyses were computed using both z- and t-statistics including a p-value ranking. Considering respective tests, a false discovery rate (FDR) adjustment of the p-values was used for multiple testing corrections, and permutation tests (n>1000) were computed to control the proportion of false discoveries (i.e. false positives, > 90% confidence). Only genes whose expression significantly differed between inflammatory HCA versus non-tumour liver tissues (considering absolute fold change > 1.5 and p-values ≤ 0.01) were selected.

Gene ontology (GO) categories that were significantly over-represented in genes significantly up-regulated or suppressed in inflammatory HCA were determined by the hypergeometric test using the web-based tool GOTree Machine (GOTM) (http://bioinfo.vanderbilt.edu/gotm/) by comparison with the distribution of the overall genes included in the HG-U133A Affymetrix array.

**Quantitative RT-PCR**

Quantitative RT-PCR was performed in duplicate as described. Ribosomal 18S RNA (R18S) was used to normalize expression data and $2^{-\Delta\Delta CT}$ method was applied. Final results were expressed as the n-fold differences in target gene expression in tested samples when compared with the mean expression value of non-tumour tissues (for tumour analysis) or with control cell line.

**DNA sequencing**

DNA sequencing was performed as described using primers provided in Supplementary Table S6. All mutations were validated by sequencing a second independent PCR product on both strands.

**Cell culture**

Hep3B cells (ATCC) were grown in DMEM supplemented with 10% fetal calf serum. For transfections, cells were plated 16h prior to transfection to produce monolayers that were 60% confluent and these were transfected by using Lipofectamine™ LTX according to the manufacturer's instructions (Invitrogen). Transfection efficiency was monitored by measuring the level of either wild-type and mutated gp130 mRNA using quantitative RT-PCR and western blot analysis. The same gp130 expression level was observed in wild-type and mutant transfected cells. 48h after transfection, cells were maintained in serum-free medium, then cells were either left untreated or were stimulated with rhIL-6 (100 ng/ml) in a serum-free medium for 3 hr, just before cell harvest and protein and RNA extraction. For luciferase assay, Hep3B cells were co-transfected with Stat3 luciferase reporter vector (pSTAT3-luc 0.5μg, Panomics) and the expression plasmid for wild type or S187_Y190del mutant (ΔS) gp130 (1μg). Two days after transfection, the cells were lysed and the luciferase activity was measured according to the manufacturer's recommendations (Promega). The activities were normalized to protein in each cell lysate.

**Generation of gp130 mutants**
A full-length gp130 open reading frame cloned in pORF9 vector was purchased from Invivogen (pORF9-hIL6ST). Mutagenesis reactions were performed using the QuickChange site-directed mutagenesis kit (Stratagen). All constructs were verified by sequencing. Using the same method, we also introduced two different epitope tags (myc and flag) at the C-terminal end in the wild-type and S187_Y190del constructs.

**Western blot analysis and immunoprecipitation**

Western blot analyses were performed as described30 using the antibodies specific for STAT3, phospho-STAT3 Tyr705, STAT1, phospho-JAK2 Tyr1007/1008 (Cell Signaling Technology, diluted 1:500), JAK2 (Santa Cruz Biotechnology, 1:500), CRP (Sigma, 1:500), gp130 (C-20 Santa Cruz Biotechnology, 1:200), and VEGF (Novus Biologicals, 1:100). The phosphorylated form of gp130 (p-gp130) was analysed by SDS-PAGE after immunoprecipitation from cell lysates containing 750 μg of proteins using 5μg of the C-20 anti-gp130 antibody. The membrane was then probed with antibodies directed against phosphotyrosine (clone 4G10, Upstate Biotechnology) and gp130 (C20). For dimerization assays, cell lysates were incubated with Protein G agarose (Pierce) and anti-flag antibody (Cell signaling technology, 1:50), at 4°C overnight. The immune complexes were sedimented, washed, separated by SDS-PAGE and analysed by Western blot using anti-flag (1:1000) and anti-myc (1:1000) antibodies. In western blot, red ponceau staining or actin (Sigma, 1:3000) expression was analysed to appreciate protein loading.

**Immunohistochemistry**

Immunohistochemistry was performed using a Dako autostainer, on paraffin sections of 10% fixed tumour tissue using 2 monoclonal antibodies against inflammatory proteins: anti-C-reactive protein (CRP), (Abcam, 1:1500), anti-serum amyloid A (SAA), (Dako, 1:50), anti-phospho-STAT3 Tyr705 (Cell signaling Technology, 1:50), anti-gp130 (C-20 Santa Cruz Biotechnology, 1:200). For inflammatory cells immunotyping, the following antibodies (Dako) were used: CD45 (clone EB11+P7D2, 1:300), CD3 (polyclonal, 1:100), CD4 (clone OPD4, 1:100), CD8 (clone C8/144B, 1:20), CD20 (clone L26, 1:100), CD68 (clone PG-M1, 1:50). For each immunohistochemical procedure, antigen retrieval was performed in citrate buffer, detection was amplified by the Dako Envision system.

**Acknowledgements:**

We are indebted to Philippe Bois (The Scripps Research Institute, Jupiter) and Olivier Bernard (InsERM E0210, Paris) for scientific discussion and critical reading of this manuscript. We warmly thank Cristel Thomas and Gaelle Cubel for their participation to this work that is dedicated to Jean-Philippe Salier (InsERM U519, Rouen). We also thank Jean Saric, Christophe Laurent, Antonio Sa Cunha, Brigitte Le Bail, Anne Rullier for contributing to the tissue collection (CHU Bordeaux). This work was supported by InsERM (Réseau de recherche clinique et recherche, Thérapeutique), the Fondation de France. S.R. and M.A. are supported by a fellowship from la Ligue Nationale contre le Cancer and the Inca, Rullier for contributing to the tissue collection (CHU Bordeaux). This work was supported by Inserm (Réseaux de recherche clinique et recherche, Thérapeutique), the Fondation de France. S.R. and M.A. are supported by a fellowship from la Ligue Nationale contre le Cancer and the Inca, respectively. JZR is supported by an interface contract between InsERM and Bordeaux hospital. TI is supported by the National Institutes of Health grants GM071596, AI055894, and AI067949.

**References:**

2. Ward LD High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem. 269: 23286- 9 1994;
3. Lutticken C Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 263: 89- 92 1994;
8. Ward LD High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem. 269: 23286- 9 1994;
19. Judd LM Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology. 126: 196- 207 2004;
33. Li C , Hung Wong W Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2: Research0032- 2001;

Figure 1
Activation of the interleukin-6 and interferon pathways in inflammatory HCA

a, Immunohistochemical analysis of CRP expression: high level of expression in tumour hepatocytes (IHCA); adjacent normal non-tumour liver hepatocytes (NTL) and inflammatory cells located in tumour (arrow) are negative. b, qRT-PCR validation of gene array expression data comparing IHCA (n=14, black) to NTL (n=6, white). Graphs plot mean +/- SD. *, **, *** difference between groups at P<0.05; 0.01 and 0.001, respectively (two-tailed Mann-Whitney test). c, Western-blot analysis comparing expression levels of STAT1 (84, 91 kDa), STAT3 (79, 86 kDa), CRP (24 kDa), VEGF (22 kDa), Jak2 and phospho-Jak2 (125 kDa) between IHCA and NTL. d, Schematic representation of the IL6 and interferon pathways showing all genes overexpressed (red) or suppressed (green) in IHCA compared to NTL. Genes validated by qRT-PCR are underlined (IHCA n=14 versus NTL n=6); others were extracted from the microarray analysis (IHCA n=4 versus NTL n=4).
Figure 2
gp130 mutations in inflammatory hepatocellular tumours

(a) The spectrum of mutations in gp130 detected in IHCA (S, signal peptide; TM, transmembrane domain). The location of the 16 deletions, the duplication (in blue), and the resulting amino acid substitutions (in yellow) identified in the D2 domain of gp130 are indicated above the wild type sequence (in bold font). The most frequent mutation is indicated in red. (b) Residues 186–192 (shown in pink stick presentation) of the D2 domain of gp130 that are deleted in IHCA are intimately involved in interactions with IL6, as shown in the crystal structure of the IL6R:IL6:gp130 complex (PDB 1P9M). IHCA deletions 173–177 and 215 (labelled in red) are also predicted to disrupt the IL6-gp130 interface. The numbering of residues corresponds to the IL6ST cDNA, which has 22 additional N-terminal residues compared to the polypeptide chain due to the nuclear export signal.
Figure 3
Gain-of-function mutations of gp130

a, Gp130 mutants (Δ) including S187_Y190del (S), Y186_Y190del (Y), V184_Y186del, S187A (V) and K173_D177del (K) or controls including gp130 wild type (Wt) and empty plasmid (EP) were transfected in Hep3B. Graphs plot qRT-PCR results relative to EP transfected unstimulated cells, mean +/- SD (transfections in triplicate). b, Graph plots luciferase activity (mean) measured in triplicate transfections ( +/- SD) with pSTAT3-luc alone or together with Wt or the ΔS gp130. Expression of total and phosphorylated (p-STAT3 and p-gp130) proteins were analysed using western blotting, after immunoprecipitation (IP) for gp130. c, CRP mRNA expression after transfection with increasing amounts of plasmids expressing Wt or ΔS gp130 (baseline, mock-transfected cells). d, Hep3B transfected with EP, Wt or ΔS gp130 and exposed to increasing concentrations of IL6. Graph plots mean CRP expression value relative to cells transfected with EP +/- SD (transfections in triplicate). e, Effect of increasing amounts of Wt gp130 on the ΔS gp130 mutant activity, without IL6. Graph plots mean level of expression of SOCS3 and CRP relative to cells transfected with EP +/- SD in duplicate (left) or in 5 independent transfections (right). f, Flag and Myc-tagged constructs expressing either the wild-type or the mutant ΔS gp130 were co-transfected (1:1) into Hep3B. gp130 dimers formation was detected after immunoprecipitation using the anti-flag antibody, followed by western blot analysis with the anti-myc and anti-flag antibodies. Shown is one representative of three independent experiments. *, **, *** indicate differences between groups at P <0.05; 0.01 and 0.001, respectively (two-tailed t-test).
Table 1

<table>
<thead>
<tr>
<th>Number of mutated tumours</th>
<th>Nucleotide change*</th>
<th>Amino acid change*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6**</td>
<td>560_571del</td>
<td>S187_Y190del</td>
</tr>
<tr>
<td>4**</td>
<td>557_571del</td>
<td>Y186_Y190del</td>
</tr>
<tr>
<td>3</td>
<td>565_576del</td>
<td>V189_V192del</td>
</tr>
<tr>
<td>2</td>
<td>563_574del</td>
<td>T188_F191del, V192I</td>
</tr>
<tr>
<td>1</td>
<td>503_580del</td>
<td>K168_N192del</td>
</tr>
<tr>
<td>1**</td>
<td>518_532del</td>
<td>K173_D177del</td>
</tr>
<tr>
<td>1**</td>
<td>551_559del</td>
<td>V184_Y186del, S187A</td>
</tr>
<tr>
<td>1</td>
<td>557_574del</td>
<td>Y186_F191del, V192F</td>
</tr>
<tr>
<td>1</td>
<td>559_573del</td>
<td>S187_F191del</td>
</tr>
<tr>
<td>1</td>
<td>564_575del</td>
<td>T188_F191del, V192T</td>
</tr>
<tr>
<td>1</td>
<td>569_577del, 578A&gt;C</td>
<td>Y190_V192del, N193S</td>
</tr>
<tr>
<td>1</td>
<td>573T&gt;G, 574_582del</td>
<td>F191L, V192_I194del</td>
</tr>
<tr>
<td>1</td>
<td>575_583del</td>
<td>V192_I194del</td>
</tr>
<tr>
<td>1</td>
<td>577_579del, 580A&gt;T</td>
<td>N193del, I194F</td>
</tr>
<tr>
<td>1</td>
<td>583_588del</td>
<td>E195_V196del</td>
</tr>
<tr>
<td>1</td>
<td>614_646dup</td>
<td>K206_P216dup, G205R</td>
</tr>
<tr>
<td>1</td>
<td>643_645del</td>
<td>D215del</td>
</tr>
</tbody>
</table>

* Codons and mutated nucleotides are numbered according to IL6ST cDNA ORF
** gp130 mutants analysed in Hep3B cells